Anagenics Ltd (AN1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anagenics Ltd (AN1) has a cash flow conversion efficiency ratio of -0.099x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-419.44K ≈ $-296.78K USD) by net assets (AU$4.23 Million ≈ $2.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AN1 market cap for the company's overall valuation and market capitalisation.
Anagenics Ltd - Cash Flow Conversion Efficiency Trend (2006–2026)
This chart illustrates how Anagenics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anagenics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anagenics Ltd ranked by their cash flow conversion efficiency. Explore how high is Anagenics Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Henderson International Income Trust PLC
LSE:HINT
|
0.024x |
|
Recrusul S/A
SA:RCSL3
|
0.257x |
|
Capitan Investment Ltd
V:CAI
|
0.042x |
|
Biophytis S.A.
NASDAQ:BPTSY
|
0.000x |
|
Inhalerx Ltd
AU:IRX
|
-0.033x |
|
ASIA Capital Group Public Company Limited
BK:ACAP
|
0.032x |
|
Neola Medical AB
ST:NEOLA
|
-0.025x |
|
Sultan Resources Ltd
AU:SLZ
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Anagenics Ltd (2006–2026)
The table below shows the annual cash flow conversion efficiency of Anagenics Ltd from 2006 to 2026. View AN1 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$4.23 Million ≈ $2.99 Million |
AU$-1.07 Million ≈ $-756.68K |
-0.253x | +70.68% |
| 2025-06-30 | AU$1.83 Million ≈ $1.29 Million |
AU$-1.58 Million ≈ $-1.12 Million |
-0.863x | -34.52% |
| 2024-06-30 | AU$2.71 Million ≈ $1.92 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.641x | -220.49% |
| 2023-06-30 | AU$8.90 Million ≈ $6.29 Million |
AU$-1.78 Million ≈ $-1.26 Million |
-0.200x | +34.30% |
| 2022-06-30 | AU$8.29 Million ≈ $5.87 Million |
AU$-2.53 Million ≈ $-1.79 Million |
-0.305x | +22.73% |
| 2021-06-30 | AU$10.43 Million ≈ $7.38 Million |
AU$-4.11 Million ≈ $-2.91 Million |
-0.394x | +3.61% |
| 2020-06-30 | AU$9.81 Million ≈ $6.94 Million |
AU$-4.01 Million ≈ $-2.84 Million |
-0.409x | +59.63% |
| 2019-06-30 | AU$5.86 Million ≈ $4.14 Million |
AU$-5.93 Million ≈ $-4.20 Million |
-1.013x | +57.27% |
| 2018-06-30 | AU$1.86 Million ≈ $1.31 Million |
AU$-4.40 Million ≈ $-3.11 Million |
-2.371x | -156.64% |
| 2017-06-30 | AU$4.40 Million ≈ $3.11 Million |
AU$-4.06 Million ≈ $-2.87 Million |
-0.924x | -70.01% |
| 2016-06-30 | AU$4.69 Million ≈ $3.32 Million |
AU$-2.55 Million ≈ $-1.80 Million |
-0.543x | +34.34% |
| 2015-06-30 | AU$3.77 Million ≈ $2.67 Million |
AU$-3.12 Million ≈ $-2.21 Million |
-0.828x | -109.28% |
| 2014-06-30 | AU$5.66 Million ≈ $4.01 Million |
AU$-2.24 Million ≈ $-1.58 Million |
-0.395x | -44.41% |
| 2013-06-30 | AU$5.31 Million ≈ $3.75 Million |
AU$-1.45 Million ≈ $-1.03 Million |
-0.274x | +67.46% |
| 2012-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.841x | +26.36% |
| 2011-06-30 | AU$2.04 Million ≈ $1.44 Million |
AU$-2.33 Million ≈ $-1.65 Million |
-1.143x | -178.85% |
| 2010-06-30 | AU$2.85 Million ≈ $2.02 Million |
AU$-1.17 Million ≈ $-826.04K |
-0.410x | +72.49% |
| 2009-06-30 | AU$738.65K ≈ $522.64K |
AU$-1.10 Million ≈ $-778.46K |
-1.489x | +41.77% |
| 2008-06-30 | AU$615.63K ≈ $435.60K |
AU$-1.57 Million ≈ $-1.11 Million |
-2.558x | -35.58% |
| 2007-06-30 | AU$1.53 Million ≈ $1.08 Million |
AU$-2.89 Million ≈ $-2.05 Million |
-1.886x | -364.75% |
| 2006-06-30 | AU$5.59 Million ≈ $3.95 Million |
AU$-2.27 Million ≈ $-1.61 Million |
-0.406x | -- |
About Anagenics Ltd
Anagenics Limited engages in the health, wellness, and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the P… Read more